ATE200225T1 - Mittel für die behandlung von störungen des blutgerinnungsprozess - Google Patents

Mittel für die behandlung von störungen des blutgerinnungsprozess

Info

Publication number
ATE200225T1
ATE200225T1 AT95916845T AT95916845T ATE200225T1 AT E200225 T1 ATE200225 T1 AT E200225T1 AT 95916845 T AT95916845 T AT 95916845T AT 95916845 T AT95916845 T AT 95916845T AT E200225 T1 ATE200225 T1 AT E200225T1
Authority
AT
Austria
Prior art keywords
apc
pct
factor
cleavage sites
agents
Prior art date
Application number
AT95916845T
Other languages
English (en)
Inventor
Johannes Jacobus Voorberg
Mourik Jan Aart Van
Koenraad Mertens
Original Assignee
Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanquin Bloedvoorziening filed Critical Sanquin Bloedvoorziening
Application granted granted Critical
Publication of ATE200225T1 publication Critical patent/ATE200225T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
AT95916845T 1994-04-22 1995-04-21 Mittel für die behandlung von störungen des blutgerinnungsprozess ATE200225T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94201116 1994-04-22
PCT/NL1995/000149 WO1995029259A1 (en) 1994-04-22 1995-04-21 Method and means for detecting and treating disorders in the blood coagulation cascade

Publications (1)

Publication Number Publication Date
ATE200225T1 true ATE200225T1 (de) 2001-04-15

Family

ID=8216820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95916845T ATE200225T1 (de) 1994-04-22 1995-04-21 Mittel für die behandlung von störungen des blutgerinnungsprozess

Country Status (11)

Country Link
US (1) US6083905A (de)
EP (1) EP0756638B1 (de)
JP (1) JP3810080B2 (de)
AT (1) ATE200225T1 (de)
AU (1) AU697205B2 (de)
CA (1) CA2188463C (de)
DE (1) DE69520569T2 (de)
DK (1) DK0756638T3 (de)
ES (1) ES2157326T3 (de)
GR (1) GR3036000T3 (de)
WO (1) WO1995029259A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3163105B2 (ja) 1994-02-14 2001-05-08 リヤクス・ユニフアーシテイト・レイデン 血栓症及び／又は活性化プロテインｃに対する弱い抗凝血応答に関連した遺伝性欠陥の存在をスクリーニングする方法
US5705395A (en) * 1994-11-14 1998-01-06 The Scripps Research Institute Method for diagnosis of thrombotic disorders
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US6531455B1 (en) * 1995-03-24 2003-03-11 The Regents Of The University Of California Delivery of polynucleotides by secretory gland expression
US5874256A (en) * 1995-06-06 1999-02-23 Rijks Universiteit Leiden Method for diagnosing an increased risk for thrombosis or a genetic defect causing thrombosis and kit for use with the same
GB9604267D0 (en) * 1996-02-29 1996-05-01 Royal Infirmary Of Edinburgh N Mutation assay
PT947585E (pt) 1998-03-19 2001-11-30 Instrumentation Lab Spa Metodo in vitro melhorado, kits e reagentes para a peaquisa de defeitos de coagulacao sanguinea
DE19858278A1 (de) * 1998-12-17 2000-06-21 Dade Behring Marburg Gmbh Verfahren zum Lokalisieren von Defekten im Gerinnungssystem
JP4676585B2 (ja) * 1999-12-24 2011-04-27 一般財団法人化学及血清療法研究所 血液凝固異常に基づく疾患の治療・予防用医薬組成物
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
EP1351986A2 (de) * 2001-01-12 2003-10-15 The American National Red Cross Verfahren und zusammensetzungen zur verminderung von heparansulfatproteoglykan-vermittelter entfernung von faktor viii
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
HUP0401985A3 (en) * 2001-11-09 2009-03-30 Novo Nordisk Healthcare Ag Pharmaceutical composition comprising factor vii polypeptides and factor v polypeptides
US7375100B2 (en) 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
US7067541B2 (en) 2003-06-04 2006-06-27 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2560756A1 (en) 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Methods and devices for reducing bleed time using vagus nerve stimulation
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
WO2006027111A1 (en) * 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
DE602005025020D1 (de) 2004-12-27 2011-01-05 The Feinstein Inst Medical Res Behandlung von entzündlichen erkrankungen durch el
CA2626690A1 (en) * 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
WO2008059043A2 (en) * 2006-11-16 2008-05-22 Crucell Holland B.V. Combination of coagulation factor viii with apc-resistant factor v
WO2008059009A2 (en) * 2006-11-16 2008-05-22 Crucell Holland B.V. Factor v mutants for hemostasis in hemophilia
US20100144620A1 (en) * 2006-11-16 2010-06-10 Crucell Holland B.V. Complementation of factor xi deficeincy by factor v mutants
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
JP2011506489A (ja) * 2007-12-20 2011-03-03 ザ ユニバーシティー オブ クイーンズランド 止血をモジュレートする組成物およびその使用法
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
CN102821814B (zh) 2009-12-23 2015-07-15 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
ITFI20110084A1 (it) * 2011-04-22 2012-10-23 Kedrion Spa Nuovo processo per la preparazione di un concentrato di fv virus inattivato a partire da plasma umano, scalabile a livello industriale.
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
WO2012154865A2 (en) 2011-05-09 2012-11-15 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
WO2017127758A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation TESTING TEST FOR STIMULATION OF NERVE WAVE
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP4069269A4 (de) * 2019-12-06 2023-12-27 The Children's Hospital Of Philadelphia Zusammensetzungen und verfahren zur modulation der faktor-viii-funktion
JP2023512447A (ja) 2020-01-13 2023-03-27 ザ ファインスタイン インスティチューツ フォー メディカル リサーチ 脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
IL302709A (en) 2020-11-13 2023-07-01 Alnylam Pharmaceuticals Inc Coagulation factor iRNA compositions (F5) and methods of using them
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins

Also Published As

Publication number Publication date
AU2319495A (en) 1995-11-16
EP0756638B1 (de) 2001-04-04
AU697205B2 (en) 1998-10-01
ES2157326T3 (es) 2001-08-16
US6083905A (en) 2000-07-04
JP3810080B2 (ja) 2006-08-16
DE69520569T2 (de) 2001-10-04
CA2188463A1 (en) 1995-11-02
JPH09512425A (ja) 1997-12-16
WO1995029259A1 (en) 1995-11-02
GR3036000T3 (en) 2001-09-28
DE69520569D1 (de) 2001-05-10
CA2188463C (en) 2007-12-11
DK0756638T3 (da) 2001-07-23
EP0756638A1 (de) 1997-02-05

Similar Documents

Publication Publication Date Title
ATE200225T1 (de) Mittel für die behandlung von störungen des blutgerinnungsprozess
AT407115B (de) Verfahren zur herstellung eines konzentrates von standardisiertem, menschlichem von willebrand-faktor
EP0796623A3 (de) Pharmazeutisches Präparat zur Behandlung von Blutgerinnungs-störungen
DE69531557D1 (de) Apoliporotein e polymorphismen und behandlung der alzheimerkrankheit
NO920125L (no) Fremgangsmaate for aa bestemme den funksjonelle aktivitetentil fritt protein s eller protein c i en plasmaproeve
ATE420654T1 (de) Behandlung von muskeldystrophien und verwandter erkrankungen
DE60126495D1 (de) Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
EP1942186A3 (de) Rekombinantes Plättchencollagen-Rezeptor-Glycoprotein VI und seine pharmazeutische Anwendung
ES2106772T3 (es) Variantes de pai-2.
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
DE69705936D1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
WO1999058098A3 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
GB9610281D0 (en) Diagnostic method and apparatus
DE20213920U1 (de) Diagnostikum zum Nachweis der den von Willebrand-Faktorspaltenden Aktivität von ADAMTS13
Rüchel et al. A probable cause of paradoxical thrombosis in zygomycosis
DE50010525D1 (de) Verfahren zur isolierung und aufreinigung von gräserpollenallergenen
Cho et al. Absence of blood clotting substances from synovial fluid
Nighoghossian et al. Free protein S spectrum in young patients with stroke
DE60311330T2 (de) Genetisches Verfahren zur Vorhersage des Glaukomarisikos
Hildebrandt The Effects of Neurofibromatosis Type 1 on Pseudoarthrosis and the Forensic Implications
JPS58220697A (ja) アンテイトロンビン−３の活性測定方法及びその方法を使用するキツト
Windt et al. The hemizona assay (HZA) as an experimental model to evaluate the inhibition of sperm binding to the murine zona pellucida by isolated zona pellucida protein
DE69635989D1 (de) Diagnostischer test für von pferdearthritisvirus verursachte krankheiten
Lastrucci et al. Development of an internal restriction control in the PCR detection of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee